This article was downloaded by: [Michigan State University] On: 18 February 2015, At: 14:40 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Human Vaccines & Immunotherapeutics Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/khvi20
Letter from the Editor a
Ronald Ellis & Eva M Riedmann a
b
Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel
b
Acquisitions Editor; Landes Bioscience; Vienna, Austria Published online: 15 May 2014.
Click for updates To cite this article: Ronald Ellis & Eva M Riedmann (2014) Letter from the Editor, Human Vaccines & Immunotherapeutics, 10:1, 1-2, DOI: 10.4161/hv.28050 To link to this article: http://dx.doi.org/10.4161/hv.28050
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.
Editor's Corner Human Vaccines & Immunotherapeutics 10:1, 1–2; January 2014; © 2014 Landes Bioscience
Letter from the Editor Ronald Ellis1,* and Eva M Riedmann2 Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel; 2Acquisitions Editor; Landes Bioscience; Vienna, Austria
1
Dear Reader, We wish you a happy and prosperous New Year!
Downloaded by [Michigan State University] at 14:40 18 February 2015
This is a special year for Human Vaccine & Immunotherapeutics (HV&I), in that it will be our 10th year of publication! We want to thank you for your support over these years, be it by submitting your own work, serving as peer-reviewer or guest-editor, or supporting our journal as a member of the editorial board. HV&I was launched in 2005 as a bimonthly publication under the name Human Vaccines, and since 2009 has been published monthly. The goal of the journal was to provide a publication platform for vaccine research and development, exclusively focused on vaccines for human use. In addition to traditional vaccines for infectious diseases, the journal also has covered immunotherapeutics as well as therapeutic vaccines in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s, and addiction. The rapid growth of research in this field prompted us to rename the journal to Human Vaccines & Immunotherapeutics in 2012. In its 10th year of publication, HV&I has become an important forum for research related to vaccines and immunotherapeutics, accessible to a wide international audience in the academic, industrial, and public sectors. Our journal is well established in the community, which is reflected by a continuous growth of high quality content and our latest impact factor of 3.136. We look forward to continue the positive development of our journal in 2014 and beyond. In addition to the steadily growing regular research submissions, the editorial team strives to provide a variety of solicited content including topical reviews, product reviews, commentaries, company profiles, and portraits of distinguished scientists in the field of vaccines and immunotherapeutics. We regularly publish a Special Issue or Special Focus on timely topics related to vaccines and immunotherapeutics. Last year, we had two Special Foci on Vaccine Acceptance (issues 9-8 and 9-12). Additional Special Focus topics are planned for 2014. HV&I also publishes Meeting Supplements where selected speakers are invited to contribute to a Special Issue or Section Feature based on presentations at a conference. In 2013, we produced a Special Issue for the World Congress on Vaccines, Immunization and Immunotherapy (issue 9-3), Special Sections on the 23rd National Immunization Conference for Health Care Workers (9-6), and the Vaccine Renaissance Conference VI (9-7), as well as a Special Issue on the DNA Vaccines 2012 conference (9-10). In this first issue of the year, we draw your attention to three studies related to Rotavirus: Rotarix efficacy in Chinese infants (Li, p. 11), safety and reactogenicity of Rotarix in infants (Buyse, p. 19), and detection of porcine circovirus type 2 DNA in feces of rotavirus vaccinees (Esona, p. 25). The Pneumococcal section contains studies on 13-valent pneumococcal conjugate universal vaccination (Martinelli, p. 33), and serotype distribution and antibiotic susceptibility of invasive S. pneumoniae (Srifuengfung, p. 40), as well as two letters discussing pneumococcal vaccination—conjugate versus polysaccharide—for older adults (Hollingsworth, p. 45 and Fedson, p. 47). Two papers related to Immunotherapy look at promise and limitations of allogeneic tumor cell vaccines (Srivatsan, p. 52) and a novel nicotine vaccine using nano-plex as a delivery vehicle (Hu, p. 64). Several contributions fall in the category Influenza: clinical experience with the Chinese domestic trivalent influenza vaccine Anflu (Liu, p. 73), age and psychological influences on immune responses to influenza vaccination (Hayney, p. 83), phase 2 results from an investigational MF59-adjuvanted tetravalent vaccine formulation (Herbiger, p. 92), telephone monitoring of adverse events
*Correspondence to: Ronald Ellis; Email: [email protected] Submitted: 12/12/2013; Accepted: 12/12/2013 http://dx.doi.org/10.4161/hv.28050
www.landesbioscience.com
Human Vaccines & Immunotherapeutics 1
during an MF59-adjuvanted H5N1 influenza vaccination campaign (Huang, p. 100), and validation of a FluoroSpot assay to monitor vaccine-specific T-cell responses (Chauvat, p. 104). The section Licensed Vaccines features a great variety of papers on making rabies prophylaxis more economical (Huang, p. 114), safety and immunogenicity of the novel rabies vaccine Vaxirab-N (Narayana, p. 120), an effective yellow fever vaccine for travelers (Verma, p. 126), twelve years of experience with the pediatric hexavalent combination vaccine Infanrix hexa (Baldo, p. 129), postmarketing safety study of a meningococcal A, C bivalent polysaccharide conjugate vaccine (Fu, p. 138), outbreak-related mumps vaccine effectiveness (Takla, p. 140), and a case of fatal varicella due to vaccine-strain varicella-zoster virus (Leung, p. 146).
Downloaded by [Michigan State University] at 14:40 18 February 2015
Five papers deal with Novel Vaccines: immunotherapeutic efficacy of a recombinant Mycobacterium smegmatis strain against persistent M. tuberculosis infection (Wang, p. 150), implications of comparative genomics for the development of a novel live attenuated tuberculosis vaccine (Zhou, p. 159), influence of adjuvant type on T-cell responses during nanoparticle-based immunization (Knuschke, p. 164), safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein vaccine (Westritschnig, p. 170), and immune response and protective efficacy induced by a multicomponent DNA vaccine against Toxoplasma gondii (Liu, p. 184). Two studies on Pertussis examine seroprevalence of pertussis in China (Xu, p. 192) and vaccine provider’s perspectives on impact, challenges and response during the California 2013 pertussis outbreak (Silvaggio, p. 199). Quality measurement and benchmarking of HPV vaccination services (Maurici, p. 208) and adolescents’ perspectives on schoollocated influenza immunization programs (Short, p. 216) are discussed in the section Public programs. Finally, the current issue features studies on Hepatitis and HPV: seroprevalence of HBV and immune response to HBV vaccination in Chinese college students (Liao, p. 224) and Guillain–Barre syndrome following quadrivalent HPV vaccination (Ojha, p. 232). A commentary on the potential impact of HIV vaccine for prevention and control of AIDS (Chawla, p. 238) and a book review on computer-aided vaccine design (Flower, p. 241) in the respective sections HIV and Technologies round out this issue. In 2014, we will continue to provide you with a selection of the latest news in the field of vaccines and immunotherapeutics in our monthly News, Policy & Profiles (NP&P) track. Among other features, this section regularly publishes portraits of distinguished scientists in the field of vaccinology and immunotherapy, and in the current issue we are pleased to present Dr Toshihiro Horii from Osaka University (Japan). Read his essay to learn more about Dr Horii’s career path and his research evolving around the development of malaria vaccines and drugs. Please contact the Acquisitions Editor Eva Riedmann ([email protected]) with your ideas for future portrait candidates. The NP&P track is also an excellent platform to share your opinion on timely, interesting, and controversial topics in the field of vaccines and/or immunotherapy. Suggestions for commentaries and opinion pieces are welcome. Last but not least, we want to draw your attention to several popular website features, which are usable on all electronic devices, such as mobile phones and tablets, an RSS feed to see the latest published papers, and a HV&I Facebook account for daily updates. Sincerely, Ronald Ellis, PhD Editor-in-Chief Eva M Riedmann, PhD Acquisitions Editor
2
Human Vaccines & Immunotherapeutics
Volume 10 Issue 1
Human Vaccines & Immunotherapeutics Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/khvi20
Letter from the Editor a
Ronald Ellis & Eva M Riedmann a
b
Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel
b
Acquisitions Editor; Landes Bioscience; Vienna, Austria Published online: 15 May 2014.
Click for updates To cite this article: Ronald Ellis & Eva M Riedmann (2014) Letter from the Editor, Human Vaccines & Immunotherapeutics, 10:1, 1-2, DOI: 10.4161/hv.28050 To link to this article: http://dx.doi.org/10.4161/hv.28050
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.
Editor's Corner Human Vaccines & Immunotherapeutics 10:1, 1–2; January 2014; © 2014 Landes Bioscience
Letter from the Editor Ronald Ellis1,* and Eva M Riedmann2 Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel; 2Acquisitions Editor; Landes Bioscience; Vienna, Austria
1
Dear Reader, We wish you a happy and prosperous New Year!
Downloaded by [Michigan State University] at 14:40 18 February 2015
This is a special year for Human Vaccine & Immunotherapeutics (HV&I), in that it will be our 10th year of publication! We want to thank you for your support over these years, be it by submitting your own work, serving as peer-reviewer or guest-editor, or supporting our journal as a member of the editorial board. HV&I was launched in 2005 as a bimonthly publication under the name Human Vaccines, and since 2009 has been published monthly. The goal of the journal was to provide a publication platform for vaccine research and development, exclusively focused on vaccines for human use. In addition to traditional vaccines for infectious diseases, the journal also has covered immunotherapeutics as well as therapeutic vaccines in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s, and addiction. The rapid growth of research in this field prompted us to rename the journal to Human Vaccines & Immunotherapeutics in 2012. In its 10th year of publication, HV&I has become an important forum for research related to vaccines and immunotherapeutics, accessible to a wide international audience in the academic, industrial, and public sectors. Our journal is well established in the community, which is reflected by a continuous growth of high quality content and our latest impact factor of 3.136. We look forward to continue the positive development of our journal in 2014 and beyond. In addition to the steadily growing regular research submissions, the editorial team strives to provide a variety of solicited content including topical reviews, product reviews, commentaries, company profiles, and portraits of distinguished scientists in the field of vaccines and immunotherapeutics. We regularly publish a Special Issue or Special Focus on timely topics related to vaccines and immunotherapeutics. Last year, we had two Special Foci on Vaccine Acceptance (issues 9-8 and 9-12). Additional Special Focus topics are planned for 2014. HV&I also publishes Meeting Supplements where selected speakers are invited to contribute to a Special Issue or Section Feature based on presentations at a conference. In 2013, we produced a Special Issue for the World Congress on Vaccines, Immunization and Immunotherapy (issue 9-3), Special Sections on the 23rd National Immunization Conference for Health Care Workers (9-6), and the Vaccine Renaissance Conference VI (9-7), as well as a Special Issue on the DNA Vaccines 2012 conference (9-10). In this first issue of the year, we draw your attention to three studies related to Rotavirus: Rotarix efficacy in Chinese infants (Li, p. 11), safety and reactogenicity of Rotarix in infants (Buyse, p. 19), and detection of porcine circovirus type 2 DNA in feces of rotavirus vaccinees (Esona, p. 25). The Pneumococcal section contains studies on 13-valent pneumococcal conjugate universal vaccination (Martinelli, p. 33), and serotype distribution and antibiotic susceptibility of invasive S. pneumoniae (Srifuengfung, p. 40), as well as two letters discussing pneumococcal vaccination—conjugate versus polysaccharide—for older adults (Hollingsworth, p. 45 and Fedson, p. 47). Two papers related to Immunotherapy look at promise and limitations of allogeneic tumor cell vaccines (Srivatsan, p. 52) and a novel nicotine vaccine using nano-plex as a delivery vehicle (Hu, p. 64). Several contributions fall in the category Influenza: clinical experience with the Chinese domestic trivalent influenza vaccine Anflu (Liu, p. 73), age and psychological influences on immune responses to influenza vaccination (Hayney, p. 83), phase 2 results from an investigational MF59-adjuvanted tetravalent vaccine formulation (Herbiger, p. 92), telephone monitoring of adverse events
*Correspondence to: Ronald Ellis; Email: [email protected] Submitted: 12/12/2013; Accepted: 12/12/2013 http://dx.doi.org/10.4161/hv.28050
www.landesbioscience.com
Human Vaccines & Immunotherapeutics 1
during an MF59-adjuvanted H5N1 influenza vaccination campaign (Huang, p. 100), and validation of a FluoroSpot assay to monitor vaccine-specific T-cell responses (Chauvat, p. 104). The section Licensed Vaccines features a great variety of papers on making rabies prophylaxis more economical (Huang, p. 114), safety and immunogenicity of the novel rabies vaccine Vaxirab-N (Narayana, p. 120), an effective yellow fever vaccine for travelers (Verma, p. 126), twelve years of experience with the pediatric hexavalent combination vaccine Infanrix hexa (Baldo, p. 129), postmarketing safety study of a meningococcal A, C bivalent polysaccharide conjugate vaccine (Fu, p. 138), outbreak-related mumps vaccine effectiveness (Takla, p. 140), and a case of fatal varicella due to vaccine-strain varicella-zoster virus (Leung, p. 146).
Downloaded by [Michigan State University] at 14:40 18 February 2015
Five papers deal with Novel Vaccines: immunotherapeutic efficacy of a recombinant Mycobacterium smegmatis strain against persistent M. tuberculosis infection (Wang, p. 150), implications of comparative genomics for the development of a novel live attenuated tuberculosis vaccine (Zhou, p. 159), influence of adjuvant type on T-cell responses during nanoparticle-based immunization (Knuschke, p. 164), safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein vaccine (Westritschnig, p. 170), and immune response and protective efficacy induced by a multicomponent DNA vaccine against Toxoplasma gondii (Liu, p. 184). Two studies on Pertussis examine seroprevalence of pertussis in China (Xu, p. 192) and vaccine provider’s perspectives on impact, challenges and response during the California 2013 pertussis outbreak (Silvaggio, p. 199). Quality measurement and benchmarking of HPV vaccination services (Maurici, p. 208) and adolescents’ perspectives on schoollocated influenza immunization programs (Short, p. 216) are discussed in the section Public programs. Finally, the current issue features studies on Hepatitis and HPV: seroprevalence of HBV and immune response to HBV vaccination in Chinese college students (Liao, p. 224) and Guillain–Barre syndrome following quadrivalent HPV vaccination (Ojha, p. 232). A commentary on the potential impact of HIV vaccine for prevention and control of AIDS (Chawla, p. 238) and a book review on computer-aided vaccine design (Flower, p. 241) in the respective sections HIV and Technologies round out this issue. In 2014, we will continue to provide you with a selection of the latest news in the field of vaccines and immunotherapeutics in our monthly News, Policy & Profiles (NP&P) track. Among other features, this section regularly publishes portraits of distinguished scientists in the field of vaccinology and immunotherapy, and in the current issue we are pleased to present Dr Toshihiro Horii from Osaka University (Japan). Read his essay to learn more about Dr Horii’s career path and his research evolving around the development of malaria vaccines and drugs. Please contact the Acquisitions Editor Eva Riedmann ([email protected]) with your ideas for future portrait candidates. The NP&P track is also an excellent platform to share your opinion on timely, interesting, and controversial topics in the field of vaccines and/or immunotherapy. Suggestions for commentaries and opinion pieces are welcome. Last but not least, we want to draw your attention to several popular website features, which are usable on all electronic devices, such as mobile phones and tablets, an RSS feed to see the latest published papers, and a HV&I Facebook account for daily updates. Sincerely, Ronald Ellis, PhD Editor-in-Chief Eva M Riedmann, PhD Acquisitions Editor
2
Human Vaccines & Immunotherapeutics
Volume 10 Issue 1
